#1 Clinical Trials Search in Europe

Tolvaptan

Tolvaptan is a medication that has been the subject of numerous clinical trials to evaluate its effectiveness and safety in treating various medical conditions. This article examines the use of Tolvaptan in clinical trials for conditions such as hyponatremia, autosomal dominant polycystic kidney disease (ADPKD), cirrhosis with ascites, and heart failure. We’ll explore the drug’s mechanisms, dosing strategies, and potential benefits across different patient populations.

Table of Contents

What is Tolvaptan?

Tolvaptan is a medication used to treat various conditions related to fluid balance in the body. It’s also known by the brand name SAMSCA[1]. Tolvaptan works by helping the body remove excess water without losing too many important salts (electrolytes)[2].

What Conditions Does Tolvaptan Treat?

Tolvaptan is used to treat several conditions:

  • Hyponatremia: This is a condition where there’s too little sodium in the blood. It can be caused by various factors, including a condition called Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)[1].
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): This is a genetic disorder that causes cysts to grow in the kidneys[3].
  • Autosomal Recessive Polycystic Kidney Disease (ARPKD): Another form of polycystic kidney disease, but it’s less common than ADPKD[4].
  • Cirrhosis with Ascites: Ascites is a buildup of fluid in the abdomen, often seen in patients with liver cirrhosis[5].
  • Heart Failure: Tolvaptan may be used in some patients with heart failure who have low sodium levels[6].

How Does Tolvaptan Work?

Tolvaptan is a type of drug called a vasopressin receptor antagonist. It works by blocking the effects of a hormone called vasopressin (also known as antidiuretic hormone). This hormone normally tells your kidneys to hold onto water. By blocking its effects, tolvaptan causes your body to release more water as urine, without losing too many electrolytes. This helps to balance the amount of water and sodium in your body[2].

How is Tolvaptan Administered?

Tolvaptan is usually taken orally (by mouth) as a tablet. The dosage can vary depending on the condition being treated and the patient’s response:

  • For adults, doses typically range from 15 mg to 90 mg per day[7].
  • It’s often given as a split dose, with a larger dose in the morning and a smaller dose about 8 hours later[7].
  • For children and adolescents, the dose is usually based on body weight[8].
  • In some cases, tolvaptan may be given through a feeding tube or nasogastric tube[2].

It’s important to take tolvaptan exactly as prescribed by your doctor. You may need frequent blood tests to check your sodium levels and kidney function while taking this medication.

Effectiveness of Tolvaptan

Research has shown that tolvaptan can be effective in treating various conditions:

  • In patients with hyponatremia, tolvaptan has been shown to effectively increase and maintain serum sodium levels[8].
  • For patients with ADPKD, tolvaptan has been demonstrated to slow the decline of kidney function[3].
  • In patients with cirrhosis and ascites, tolvaptan may help reduce the need for procedures to remove excess fluid (paracentesis)[5].

Potential Side Effects

Like all medications, tolvaptan can cause side effects. Some of the most common include:

  • Increased urination
  • Thirst
  • Dry mouth
  • Constipation or diarrhea
  • Weakness

In rare cases, tolvaptan can cause more serious side effects, including liver problems. Your doctor will monitor you closely for any signs of these issues[9].

Use in Special Populations

Tolvaptan is being studied for use in various populations:

  • Children and Adolescents: Research is ongoing to determine the safety and effectiveness of tolvaptan in younger patients with conditions like ARPKD[4].
  • Patients with Heart Devices: Studies are looking at the use of tolvaptan in patients with left ventricular assist devices (LVADs)[6].

Ongoing Research

Scientists continue to study tolvaptan to better understand its effects and potential uses. Some areas of ongoing research include:

  • Long-term safety and effectiveness in patients with ADPKD[9]
  • Use of tolvaptan in children and adolescents with various conditions[4][8]
  • Different formulations of tolvaptan, including modified-release versions[3]
  • Use of lower doses in certain populations[10]

As with any medication, it’s important to discuss the potential benefits and risks of tolvaptan with your healthcare provider. They can help determine if this medication is appropriate for your specific situation.

Aspect Details
Primary Conditions Studied Hyponatremia, Autosomal Dominant Polycystic Kidney Disease (ADPKD), Cirrhosis with Ascites, Heart Failure
Dosage Range 7.5 mg to 120 mg daily, depending on condition and trial protocol
Administration Method Oral tablets, either as single or split doses
Primary Mechanism Blocks effects of vasopressin, promoting water excretion without electrolyte loss
Key Outcomes Measured Changes in serum sodium levels, urine output, body weight, ascites volume, kidney function
Common Side Effects Increased urination, thirst, dry mouth
Trial Durations Ranging from a few days to several months or years
Special Populations Studies include adults, children, and adolescents in some trials

FAQ

  • What is Tolvaptan and how does it work? Tolvaptan is a medication that works by blocking the effects of a hormone called vasopressin. This action helps the body to remove excess water without losing important electrolytes like sodium. It's primarily used to treat conditions where the body retains too much water, such as in certain types of heart failure or kidney disease.
  • In which medical conditions is Tolvaptan being studied? Tolvaptan is being studied in various conditions, including hyponatremia (low blood sodium levels), autosomal dominant polycystic kidney disease (ADPKD), cirrhosis with ascites (fluid buildup in the abdomen), and heart failure. Clinical trials are exploring its effectiveness in managing symptoms and improving outcomes in these conditions.
  • How is Tolvaptan administered in clinical trials? In clinical trials, Tolvaptan is typically administered orally as tablets. The dosage can vary depending on the condition being treated and the specific trial protocol. For example, doses may range from 7.5 mg to 120 mg per day, and may be given as a single dose or split into two doses taken at different times of the day.
  • What are some potential side effects of Tolvaptan? Common side effects of Tolvaptan can include increased urination, thirst, and dry mouth. In some cases, it may cause more serious side effects such as rapid changes in blood sodium levels. Clinical trials closely monitor patients for these and other potential adverse effects to ensure safety.
  • How long do clinical trials for Tolvaptan typically last? The duration of Tolvaptan clinical trials can vary widely depending on the condition being studied and the specific goals of the trial. Some trials may last only a few days or weeks, while others, particularly those studying long-term effects in chronic conditions like ADPKD, may continue for several months or even years.

Ongoing Clinical Trials on Tolvaptan

  • Study Comparing Metformin and Tolvaptan for Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Poland Spain

  • Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium France Germany The Netherlands Spain

  • Study on the Safety and Effects of Tolvaptan for Infants and Young Children with Autosomal Recessive Polycystic Kidney Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Poland Spain

Glossary

  • Hyponatremia: A condition where the level of sodium in the blood is abnormally low. This can cause symptoms such as nausea, headache, confusion, and in severe cases, seizures or coma.
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): A genetic disorder characterized by the growth of numerous cysts in the kidneys, which can lead to kidney failure over time.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism.
  • Ascites: The accumulation of fluid in the abdominal cavity, often as a result of liver disease.
  • Vasopressin: Also known as antidiuretic hormone (ADH), it is a hormone that plays a key role in regulating water retention in the body.
  • Bioavailability: The proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A condition in which the body makes too much antidiuretic hormone (ADH), causing the body to retain water and lowering sodium levels in the blood.
  • Glomerular Filtration Rate (GFR): A test used to check how well the kidneys are working. Specifically, it estimates how much blood passes through the glomeruli each minute.
  • Left Ventricular Assist Device (LVAD): A mechanical pump that's used to support heart function and blood flow in people who have weakened hearts.

References

  1. https://clinicaltrials.gov/study/NCT04790175
  2. https://clinicaltrials.gov/study/NCT01261481
  3. https://clinicaltrials.gov/study/NCT01210560
  4. https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolvaptan-for-children-with-autosomal-recessive-polycystic-kidney-disease-arpkd/
  5. https://clinicaltrials.gov/study/NCT01292304
  6. https://clinicaltrials.gov/study/NCT05408104
  7. https://clinicaltrials.gov/study/NCT01349348
  8. https://clinicaltrials.gov/study/NCT02012959
  9. https://clinicaltrials.gov/study/NCT02251275
  10. https://clinicaltrials.gov/study/NCT06171100